UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

SERUM AMYLOID P-COMPONENT PREVENTS PROTEOLYSIS OF THE AMYLOID FIBRILS OF ALZHEIMER-DISEASE AND SYSTEMIC AMYLOIDOSIS

TENNENT, GA; LOVAT, LB; PEPYS, MB; (1995) SERUM AMYLOID P-COMPONENT PREVENTS PROTEOLYSIS OF THE AMYLOID FIBRILS OF ALZHEIMER-DISEASE AND SYSTEMIC AMYLOIDOSIS. P NATL ACAD SCI USA , 92 (10) 4299 - 4303.

Full text not available from this repository.

Abstract

Extracellular deposition of amyloid fibrils is responsible for the pathology in the systemic amyloidoses and probably also in Alzheimer disease [Haass, C. and Selkoe, D. J. (1993) Cell 75, 1039-1042] and type II diabetes mellitus [Lorenzo, A., Razzaboni, B., Weir, G. C. and Yankner, Il. A. (1994) Nature (London) 368, 756-760]. The fibrils themselves are relatively resistant to proteolysis in vitro but amyloid deposits do regress in vivo, usually with clinical benefit, if new amyloid fibril formation can be halted. Serum amyloid P component (SAP) binds to all types of amyloid fibrils and is a universal constituent of amyloid deposits, including the plaques, amorphous amyloid beta protein deposits and neurofibrillary tangles of Alzheimer disease [Coria, F., Castano, E., Prelli, F., Larrondo-Lillo, M., van Duinen, S., Shelanski, M. L. and Frangione, B. (1988) Lab. Invest. 58, 454-458; Duong, T., Pommier, E. C. and Scheibel, A. B. (1989) Acta Neuropathol. 78, 429-437]. Here we show that SAP prevents proteolysis of the amyloid fibrils of Alzheimer disease, of systemic amyloid A amyloidosis and of systemic monoclonal light chain amyloidosis and may thereby contribute to their persistence in vivo. SAP is not an enzyme inhibitor and is protective only when bound to the fibrils. Interference with binding of SAP to amyloid fibrils in vivo is thus an attractive therapeutic objective, achievement of which should promote regression of the deposits.

Type: Article
Title: SERUM AMYLOID P-COMPONENT PREVENTS PROTEOLYSIS OF THE AMYLOID FIBRILS OF ALZHEIMER-DISEASE AND SYSTEMIC AMYLOIDOSIS
Keywords: C-REACTIVE PROTEIN, BLOOD-BRAIN-BARRIER, AA-AMYLOIDOSIS, SENSITIVE SITE, DEPOSITS, PLAQUES, INVITRO, IMMUNOREACTIVITY, ASSOCIATION, CONSTITUENT
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Surgery and Interventional Sci
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Surgery and Interventional Sci > Department of Targeted Intervention
URI: http://discovery.ucl.ac.uk/id/eprint/152688
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item